Podcasts about Efficacy

In mid-December 2025, the FDA approved an at home devicethat aims to treat depression by sending electric current into a part of the brain (the prefrontal cortex) known to regulate mood. This has been available in the UK since 2019 but it is new to the US. The manufacturer has stated that over 55,000 patients have used the device across Europe, the UK, Switzerland, and Hong Kong. How does this work? Is there data to support this new therapy? In this episode, we will summarize three consecutive years of data (2023, 2024,2025) to answer that question. Listen in for details. 1.     Sci Amer: https://www.scientificamerican.com/article/u-s-approves-first-device-to-treat-depression-with-brain-stimulation-at-home/2.     August 12, 2023: Burkhardt, Gerrit et al.Transcranial direct current stimulation as an additional treatment to selectiveserotonin reuptake inhibitors in adults with major depressive disorder inGermany (DepressionDC): a triple-blind, randomised, sham-controlled,multicentre trial The Lancet, Volume 402, Issue 10401, 545 – 5543.     October 21, 2024: Woodham, R.D., Selvaraj, S.,Lajmi, N. et al. Home-based transcranial direct current stimulation treatmentfor major depressive disorder: a fully remote phase 2 randomizedsham-controlled trial. Nat Med 31, 87–95 (2025). https://doi.org/10.1038/s41591-024-4.     December 15, 2025: Moshfeghinia R, Bordbar S,Roointanpour Y, Arab Bafrani M, Shalbafan M. Efficacy and safety of home-basedtranscranial direct current stimulation (tDCS) on patients with depressivedisorders: a systematic review and meta-analysis of randomized clinical trials.Sci Rep. 2025 Dec 15;15(1):43850. doi: 10.1038/s41598-025-28648-5. PMID:41398008; PMCID: PMC12705823.

Send us a textTo close out 2025, we are revisiting our top podcast episodes of 2025, including this one discussing creatine and mental health with creatine researcher, Dr. Riccardo De Giorgi.We spoke with Dr. Riccardo De Giorgi about:His published study, "Efficacy and safety profile of oral creatine monohydrate in add-on to cognitive-behavioural monohydrate in depression: An 8-week pilot, double blind, randomised, placebo-controlled feasibility and exploratory, placebo-controlled feasibility and exploratory trial in an under-resourced area"Where he'd like to see additional research Dr Riccardo De Giorgi is Clinical Lecturer at the University of Oxford, Department of Psychiatry, and ST6 at Health Education England-Thames Valley, Oxford Health NHS Foundation Trust. He is interested in neuropsychopharmacology and evidence-based treatment of mental illness, especially mood disorders. He works on evidence synthesis, epidemiological, and experimental medicine studies to investigate repurposing opportunities for drugs with immuno-metabolic activity (e.g., statins, GLP1-RAs) in psychiatric disorders. Please note that this podcast is created strictly for educational purposes and should never be used for medical diagnosis or treatment.Connect w/ Dr. Riccardo De GiorgiX: https://x.com/rdegiorgi?lang=enLinkedIn: https://uk.linkedin.com/in/riccardo-de-giorgi-59437b255Oxford: https://www.psych.ox.ac.uk/team/riccardo-de-giorgiMentioned:Shop Kyla's favorite third party tested, certified safe for sport Creatine Monohydrate at 20% off MSRP: https://us.fullscript.com/welcome/kchannellMORE NR New customers save 10% off all products on our website with the code NEWPOD10 If you would like to work with our practitioners, click here: https://nutritional-revolution.com/work-with-us/ Save 50% off your 1st Trifecta Nutrition order with code NR50: https://trifectanutrition.llbyf9.net/qnNk05 Save 20% on all supplements at our trusted online source: https://us.fullscript.com/welcome/kchannell Join Nutritional Revolution's The Feed Club to get $20 off right away with an additional $20 Feed credit drop every 90 days.: https://thefeed.com/teams/nutritional-revolution If you're interested in sponsoring Nutritional Revolution Podcast, shoot us an email at nutritionalrev@gmail.com.

In this podcast episode, Rami Komrokji, MD, reviews data from select presentations in myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs) presented at the ASH 2025 Annual Meeting and shares expert perspectives on the clinical implications of these findings, including:Abstract 910: MANIFEST-2 96-Wk Update: Ruxolitinib + Pelabresib or Placebo in Patients With JAK Inhibitor–Naive MFAbstract 1024: Phase I Trial of INCA033989, a First-in-Class Antibody Targeting Mutant Calreticulin: Safety and Efficacy in Essential ThrombocythemiaAbstract 484: Preliminary Results From 2 Phase I Trials Exploring the Mutant Calreticulin-Specific mAb INCA033989 ± Ruxolitinib in Patients With MFAbstract 235: VERONA: Subgroup Analyses of Venetoclax or Placebo Combined With Azacitidine in Treatment-Naive Higher-Risk MDSAbstract 490: IMerge Post Hoc Analysis: Treatment-Emergent Cytopenias and Response With Imetelstat in Patients With Lower-Risk MDSAbstract 487: Randomized Phase II Trial of Reduced Treatment Durations of Hypomethylating Agents for Lower-Risk MDSPresenter: Rami Komrokji, MDSenior Member, Vice ChairSection Head – Leukemia and MDSDepartment of Malignant HematologyH. Lee Moffitt Cancer CenterProfessor of Oncologic SciencesUniversity of South FloridaTampa, FloridaContent based on an online CME program supported by educational grants from AstraZeneca, BeOne Medicines, Genentech, Geron Corporation, Incyte, Johnson & Johnson, Lilly, and Novartis Pharmaceuticals Corporation.Link to full program: https://bit.ly/48Ye45N Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Efficacy of InsignificanceLuke 2:1-7

CardioNerds (Dr. Colin Blumenthal, Dr. Kelly Arps, and Dr. Natalie Marrero) discuss anti-arrhythmic drugs in the management of atrial fibrillation and atrial flutter with electrophysiologist Dr. Andrew Epstein. We discuss two major classes of anti-arrhythmic drugs, class IC and class III, as well as digoxin. Dr. Epstein explains their mechanisms of action, indications and specific patient populations in which they would be particularly helpful, efficacy, adverse side effects, contraindications, and key drug-drug interactions. We also elaborate on defining clinical trials and their clinical implications. Given the large burden of atrial fibrillation and atrial flutter in our patient population and the high prevalence of anti-arrhythmic drug use, this episode is sure to be applicable to many practicing physicians and trainees. Audio editing by CardioNerds academy intern, Grace Qiu.  Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls Anti-arrhythmic drugs should not be thought of as an alternative to ablation but, instead, should be considered an adjunct to catheter ablation.   Class IC anti-arrhythmic drugs, flecainide and propafenone, are highly efficacious for acute cardioversion and a great option for patients with infrequent episodes of AF who do not have a history of ischemic heart disease.    Class III anti-arrhythmic drugs like ibutilide, sotalol, and dofetilide, are highly effective for acute conversion; however, they require hospitalization for close monitoring during initiation and dose titration given the risk of prolonged QT.   Amiodarone should not be used as a first line agent given its toxicities, prolonged half-life, large volume of distribution, and drug-drug interactions.   Dr. Epstein notes that, “All drugs are poisons with a few beneficial side effects,” when highlighting the many adverse side effects of anti-arrhythmic drugs, particularly amiodarone, and the importance of balancing their benefit in rhythm control with their side effect profile.   Notes Notes: Notes drafted by Dr. Natalie Marrero. What are the Class IC anti-arrhythmic drugs and what indications exist for their use?   Class IC anti-arrhythmic drugs are anti-arrhythmic drugs that work by blocking sodium channels and, thereby, prolonging depolarizing.   Class IC anti-arrhythmic drugs include flecainide and propafenone.   Class IC anti-arrhythmic drugs are good agents to use in patients that have infrequent episodes of AF and do not want daily dosing as these agents can be used by patients when they feel palpitations and desire acute conversion back to sinus rhythm (“pill in the pocket” approach).    What are the adverse consequences and/or contraindications to using a class IC agent?  Class IC anti-arrhythmic agents are contraindicated in patients with a history of ischemic heart disease based on increased mortality associated with their use in these patients in the CAST trial.   Given the results of the CAST trial, providers should screen annually for ischemia via a functional stress test in patients on these drugs at risk for coronary disease.   These drugs can increase 1:1 conduction of atrial flutter and, therefore, require concomitant use of a beta blocker.   These agents are generally well-tolerated without any organ toxicities; however, they can precipitate heart failure in patients with cardiomyopathies, cause sinus node depression, and unmask genetic arrythmias such as a Brugada pattern.   What are the class III agents and what are indications for their use?   Class III agents are drugs that block the potassium channel, prolonging the QT, and include Ibutilide, Sotalol, and Dofetilide.    Class III agents can be considered in patients with or without a history of ischemic heart disease that desire effective acute chemical cardioversion and are willing to go to the hospital for close monitoring during dose initiation and titration.   Other specific circumstances in which one can use these agents, specifically Ibutilide, are in patients with recurrent atrial fibrillation and Wolf Parkinson White (due to slowed conduction via the accessory pathway).  What are the adverse consequences and/or contraindications to using a class III agent?  Ibutilide, Sotalol, and Dofetilide prolong the QT and increase the risk of torsade de pointes, which is why they require ECG monitoring in-patient during drug initiation and dose titration.    These agents are generally well-tolerated.   Sotalol should be avoided or used cautiously in patients with left ventricular dysfunction, while dofetilide can be used and has dose-response beneficial effects in patients with left ventricular dysfunction.   Both sotalol and dofetilide are renally cleared with specific creatinine clearance cutoffs (CrCl < 20 for dofetilide and CrCl

In this episode, Dr. Steve Gard, editor-in-chief of the Journal of Prosthetics and Orthotics, sits down with Tiffany Graham, MSPO, CPO, LPO, FAAOP(D), to discuss her research on the effectiveness of 3D-printed cranial remolding orthoses (CROs) for infants. Tiffany walks through the evolution of CRO design—from early fabrication techniques to today's innovative 3D-printing approaches—and shares insights from a recent study conducted in Australia. Their conversation highlights key findings showing that 3D-printed CROs are a successful treatment option for cranial deformities, with some head shapes potentially requiring longer intervention. They also explore the practical benefits of 3D-printed devices, including improved ventilation, which may offer meaningful advantages for patients in warmer climates. Show notes JPO article: Efficacy of 3D-Printed Cranial Remolding Orthosis for Infants in Australia   O&P Research Insights is produced by Association Briefings.

5. Symbolic Strikes: US and Jordan Target Resurgent ISIS in Syria. Following an attack on US personnel, the US and Jordan conducted airstrikes against ISIS strongholds, likely with Syrian regime consultation. Ahmed Sharawi questions the efficacy of striking desert warehouses when ISIS cells have moved into urban areas, suggesting the strikes were primarily symbolic domestic messaging. 1898 DAMASCUS

Show SummaryOn today's episode, we're featuring a conversation with Marine Corps Veteran Andy Gasper, CEO and President of Warrior Foundation Freedom Station, a nonprofit organization that has created Freedom Stations, recovery transition centers and housing facilities that provide injured Warriors with the acclimation time, guidance and resources to successfully make the transition from military service to civilian lifeProvide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestAndy Gasper is the President and CEO of Warrior Foundation Freedom Station, a nonprofit organization dedicated to supporting wounded, ill, and injured service members as they transition from military service to civilian life. Warrior Foundation Freedom Station provides transitional housing, peer support, mentorship, financial and career guidance, wellness services, and community connection through its Freedom Station residences in San Diego, helping medically retiring warriors prepare for long-term success.Under Andy's leadership, the foundation has expanded its mission to include a structured 18-month transitional housing program that offers wraparound support services designed to empower residents to pursue education, careers, and independent living. The program integrates peer-to-peer support, counseling, mentorship, and practical life guidance to foster meaningful community and improved quality of life for veterans navigating the challenges of recovery and civilian transition.A Marine Corps veteran himself, Andy brings both lived experience and professional commitment to his work, emphasizing the importance of community, dignity, and holistic support for America's warriors. Under his stewardship, Warrior Foundation Freedom Station has opened multiple transitional housing facilities and continues to scale its impact to serve more medically retiring service members and their families.Warrior Foundation Freedom Station supports service members and veterans who are seriously ill or injured, affected by post-traumatic stress or traumatic brain injury, undergoing therapy, or navigating medical retirement and reintegration into civilian life.Links Mentioned During the EpisodeWarrior Foundation WebsiteWarrior Foundation VideoPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is The PsychArmor course How to Build a Successful Transition Plan. Join General Peter Chiarelli, United States Army (Ret.), in PsychArmor's course “How to Build a Successful Transition Plan” as he discusses the importance of setting realistic expectations, goal-setting, and flexibility during your transition. You can find the resource here:  https://learn.psycharmor.org/courses/How-to-Build-a-Successful-Transition-Plan Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In this episode of the Award-winning PRS Journal Club Podcast, 2026 Resident Ambassadors to the PRS Editorial Board – Lucas Harrison, Christopher Kalmar, and Priyanka Naidu- and special guest, Shai Rozen, MD, discuss the following articles from the January 2026 issue:   "The Efficacy of Flap Debulking after Facial Reanimation Surgery to Enhance Facial Symmetry" by Weiss, Fricke, Hohenstein, et al.   "The Natural Progression of Synkinesis" by Rail, Bhatia, Dragun, et al.   "Extended Sural Nerve Harvest: A Technique to Gain Additional Graft Length" by Millesi, Gates-Tanzer, Felzen, et al.   Special guest, Shai Rozen is Professor and Vice-Chairman in the Department of Plastic Surgery at the University of Texas Southwestern Medical Center and Director of the Facial Reanimation Program, specializing in treating patients with facial paralysis. He completed both general surgery and plastic surgery training at Johns Hopkins, followed by fellowships in both craniofacial and peripheral nerve surgery.    READ the articles discussed in this podcast as well as free related content: https://bit.ly/JCJan26Collection   The views expressed by hosts and guests are their own and do not necessarily reflect the official policies or positions of ASPS.

Alan Beggs, PhDDirector of the Manton Center for Orphan Disease ResearchSir Edwin and Lady Manton Professor of Pediatrics, Boston Children's HospitalHarvard Medical School, Boston, MA, USA Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAThe ASPIRO Clinical Trial is on clinical hold since September 2021. In this part, Doctors Beggs and Parsons will discuss key issues on gene therapy development.Question: Is there a standardized immunomodulation regimen being considered for gene therapy?Julie A. Parsons, MDAs I mentioned, right now, I think there are a number of different concepts that are being utilized. We don't really have a recommended standard regimen at this point. There are a number of different trials that are ongoing looking at trying to answer this question. In some of the clinical trials, there is an immune modulating regimen that is being put in place but being looked at. There isn't anything that we have as a standard at this moment for all gene transfer therapies, but I'm hopeful that we will come up with something that really makes sense in each patient population as we go forward with specific gene transfer therapies.Question: What are the long-term implications, safety and efficacy of a one-time gene therapy in pediatric patients with neuromuscular diseases?Alan Beggs, PhDOne question is the efficacy. For example, Donovan Decker's story, he had an experimental treatment of one muscle. It was a phase one safety trial, and he knew that nothing was going to come of it in terms of direct benefit to him. As a result, though, 25, 30 years later, he still has a tighter against AAV vectors. He's not a candidate for gene therapy under current protocols, although there's a lot of work going on to redosing. But for now, it's a one-time treatment. What you get is what you get, and there's not a chance to go back and do it again.The other question is durability. We really don't know about the long-term durability for these treatments. I should say that, for example, in the studies that we did, David Mack, who's here in the audience, managed a dog colony for a dog model of excellent tubular myopathy. Those animals lived 10 years in a... We never used the C-word, but they were cured. They were healthy, happy, normal dogs who would have had to be put down at 6 months of age otherwise. And then, as we heard, I'll let you talk about the concern for unanticipated SAEs as time goes on, but I think there's other aspects we need to think about.Julie A. Parsons, MDYeah. I think that this is really the key question that all of us are going to need to help answer over the next several years. Efficacy, we're looking at outcomes, and outcomes come in a variety of flavors. I think we do a decent job with motor outcomes. We don't do a decent job with some other outcomes. I think we need to look more broadly in terms of what we mean in terms of beneficial outcomes and really take some of those cues from the patients themselves about if these are efficacious treatments, because, again, the risk is high as we deliver these agents, and we need to know that it's worth it to the patients and families.In terms of safety, we're working on it. There are all sorts of things that are coming forward as issues with these patients. I think that collectively as a community, that our responsibility is to follow patients for the long term. There are lots of registries and outcome studies. We're not very good as a community about reporting adverse events to central groups. We're not great about broadcasting that to each other in real-time. I think those are things that we really need to work on as a community in terms of helping with the safety issues so that we all have a communal better understanding of what some of those issues are.

Julie A. Parsons, MDHaberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAThe gene transfer trials for musculoskeletal disorders, if we look at musculoskeletal and neurologic disorders, we really do have the highest success rate in terms of treatment, but we also carry the highest incidence of treatment-emergent severe adverse events. And why is that true? Yesterday, when we were hearing about Donovan as well, we looked and said, When the first gene transfer therapies were started, he had a single muscle that was injected.When we look at Luxturna, we injected the retina. Now, what is happening with these disorders is that we're giving these huge, massive doses of viral vector to patients. There haven't been a lot of gene transfer therapies that have reached the market. But you saw yesterday, so many gene transfer therapies being worked on, but there are very few that have actually come to market. There are a couple of reasons for that.One is with the indications that we have, we know that the musculoskeletal disorders are most likely to achieve benefit, but there are the high risk of severe adverse events. Route of Administration, IV, for most of our disorders is the way we're going. We may end up having some Intrathecal therapies as well that are coming on board, but right now it's IV, and that means, a huge dose of this viral vector and antigenic risk that is being administered.In the vector design now, we actually have more specific vectors as well as promoters that are being utilized to really target specific tissues, so that we're able to focus in a little bit more on the tissues that we want to have affected. And then the dose has gone from these little tiny local injections to really systemic, much broader. And now our patients, are larger. So we're giving a viral genome per kilo dose that is just massive as we look at that.Then there really are challenges in terms of the translation of clinical trials to commercial treatment with these agents. And we don't always know, we're not always great when we do tests in clinical trials in small populations, about when that's broadened to the commercial availability and we hit larger heterogeneous populations.There are safety issues arising from these therapies, and I think that we have some experience now, certainly with the three diseases that I mentioned at the beginning, in terms of collecting some data and information to have a little bit more of an idea what to expect. Although to me, the recurring esteem is always, expect the unexpected. Because we still are learning about this. Hepatotoxicity. We know that transaminitis is something that we see in almost every gene transfer therapy that has been delivered, and we have to watch really, really closely and follow our patients closely for this. We also have to select patients that we don't think have risk for additional liver injury or underlying liver pathology, because as we found out in the XLMTM boys, we missed that. Thrombotic Microangiopathy. We look at this disorder. We've had deaths in SMA from TMA. We have Duchenne patients that have had TMA.This is scary because as many of us as clinicians who have treated patients, you know that we end up getting thrombocytopenia. So is that it this time, or are they going to be fine, or the platelet is going to go back to normal? This is another one that we have to watch really, really closely for. Cardiac Toxicity. We have had cardio myositis. We've had deaths from cardiac toxicity.Something really, really important for us to think about. In little kids, vomiting could be a sign of cardiac myositis. And for most of us who've treated patients with gene transfer therapy, what's one of the first issues that you get?You get nausea of vomiting, they don't feel good. So is that myocarditis or is it just a standard side effect that we're seeing with treatment? Importantly, as we discovered, there actually can be an immune response to the transgene. It's not just the viral vector capsid, it's actually the transgene as well. That was discovered in patients who were treated for Duchenne. So that's a really important thing in terms of looking now at what's our patient's selection and how do we pick the right patients.Next part, Dr. Parsons will discuss understanding and preparing risk factors associated with AAV gene therapies.

Julie A. Parsons, MD Haberfield Endowed Chair in Pediatric Neuromuscular DisordersProfessor of Clinical Pediatrics and NeurologyUniversity of Colorado School of Medicine, Children's Hospital ColoradoAurora, CO, USAAs we talk about the gene transfer therapies and the modalities that we have to use, it's really interesting. Yesterday, with our keynote speaker, you could see this logarithmic growth of the use of gene transfer therapies for these disorders. If you look at the Venn diagram, you can see that really 27% almost of gene transfer therapies that are used are in musculoskeletal and neurology. For many of us as neurologists, we also take care of metabolic disorders.We really own right now this landscape, and of course, our two approved modalities are Onasemnogene and Delandistrogene. We're going to look at three different disorders, monogenic disorders, monogenic diseases, to typify what we look at in terms of some of the risks and benefits of these treatments. SMA, Duchenne, and X-linked myotubular myopathy are all rare disorders. They're all diseases that have a high unmet medical need and a significant disease burden.I think they're all good in terms of typifying where we are clinically with these disorders. The first question is, is it worth it? Are these effective treatments? We know from looking at the information about SMA that just looking early on, we know that if we treat kids early, that we do see a marked improvement in motor scores for kids that are treated early with Onasemnogene.In Duchenne, we have information that there is at least some improvement in the 4-5-year-olds in terms of motor skills treated with Delandistrogene. In terms of X-linked MTM, which was a very dramatic improvement, you could see that for boys who were basically traked, vented, and had no mobility, the bottom line, the blue line, is actually looking at ventilator dependence. Are they effective? Yeah, they're effective, but then we have to say, okay, what's the downside?The downside is that there's tremendous risk associated with treatment with these agents. If we really look at the sobering facts, we know that with SMA, there have been deaths, there have been fatalities related to thrombotic microangiopathy to patients who have liver failure, a couple of patients have died. With Onasemnogene, this is 4,000 plus doses that have so far been given. With Duchenne, unfortunately, many of us got the letter yesterday talking about an additional death in a patient treated with commercial Delandistrogene.We also know with some of the other agents, like fordadistrogene, patient died of heart failure, cardiac arrest, another patient who had acute respiratory syndrome with pulmonary edema. Again, we look at this and say this is significant. With X-linked MTM, as Alan said, there were some unanticipated deaths, four deaths from patients who ended up having cholestatic liver diseases that really wasn't anticipated prior to the patients being treated with the animal models and all that we had. Then many of you have heard about the patient with Rett syndrome who had a systemic hyperinflammatory syndrome. Again, these are rare disorders. They have a high disease burden, but the risk of treatment is significant.In the next part, Dr. Parsons discuss factors impacting safety and efficacy of AAV-mediated gene therapies.

Episode 168 - Zwift Racing, Snorkel Training, and Should You Be Increasing Lean Mass for Improved Glycogen Stores? Hello everyone. Welcome to the latest episode of The Matchbox Podcast powered by Ignition Coach Co. I'm your host, Adam Saban, and on this week's episode we talk about Zwift Racing, Snorkel Training, and whether or not you should be chasing those lean mass muscle gains in search of increased glycogen storage.   As always, if you like what you hear, share this with your friends and leave us a five star review and if you have any questions for the show drop us an email at matchboxpod@gmail.com or head over to ignitioncoachco.com and fill out The Matchbox Podcast listener question form.    Alight let's get into it!   For more social media content, follow along @ignitioncoachco @adamsaban6 @dizzle_dillman @dylanjawnson @kait.maddox     https://patreon.com/MatchboxPodcast?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLink   https://www.youtube.com/c/DylanJohnsonCycling https://www.ignitioncoachco.com  https://www.youtube.com/@DrewDillmanChannel   Intro/ Outro music by AlexGrohl - song "King Around Here" - https://pixabay.com/music/id-15045/    The following was generated using Riverside.fm AI technologies   Summary In this conversation, the hosts discuss various aspects of Zwift racing, including training structure, the nature of Zwift races, and how to balance racing with endurance training. They also debunk the myth of snorkel training for fitness and explore the relationship between muscle mass and glycogen storage, concluding that while muscle mass can be beneficial, it may not significantly impact glycogen storage for endurance athletes.     Chapters 00:00 Introduction to Zwift Racing and Training Structure 07:04 Understanding the Nature of Zwift Racing 11:36 Balancing Intensity and Recovery in Training 14:24 Exploring Snorkel Training and Breathing Techniques 14:45 Debunking Altitude Training Myths 17:34 Understanding Respiratory Training Devices 21:52 Evaluating the Efficacy of Snorkel Training 24:18 The Role of Muscle Mass in Glycogen Storage 27:33 Strength Training and Endurance Performance  

This week on The Beat, CTSNet Editor-in-Chief Joel Dunning speaks with Dr. Nasser Altorki, thoracic surgeon at Weill Cornell Medicine in New York, and thoracic surgeon and CTSNet Senior Editor Leanne Ashrafian about the 10-year results from the JCOG0802 trial. Chapters 00:00 Intro 02:56 JANS 1, Re-Repair vs Replacement 05:07 JANS 2, Mini Mitral Multicentre RCT 07:01 JANS 3, PERSEVERE Study 08:54 JANS 4, Parietal Pleurectomy vs Pleural Abrasion 11:38 Career Center 12:33 Video 1, Endoscopic Post-Infarction VSD Repair 14:11 Video 2, 3D Dor Procedure & MVR Huge LV Aneurysm 15:19 Video 3, Non-Cardioplegic Myo Protection Robotic 17:16 Nasser Altorki Interview, JCOG 45:16 Upcoming Events 47:20 Closing They discuss key aspects of the trial, including the noninferiority primary endpoint. Dr. Altorki shares his overall thoughts on the trial, and they also examine topics such as pulmonary function, lobar vs sublobar resection, and segmentectomy vs wedge resection. Additionally, they explore secondary primary lung cancer, the importance of thoracic surgeons presenting data to patients, and best practices for segmentectomy to ensure patient safety. They also examine good wedge resection vs bad wedge resection, planning for segmentectomy, and the future of lobectomy and segmentectomy.   Joel also highlights recent JANS articles on the outcomes of re-repair vs replacement after failed primary mitral regurgitation repair, minimally invasive thoracoscopically-guided right minithoracotomy vs conventional sternotomy for mitral valve repair, one-year results of novel aortic arch hybrid prosthesis for repair of acute DeBakey Type I dissection with malperfusion, and a meta-analysis of efficacy and safety of parietal pleurectomy vs pleural abrasion in treating spontaneous pneumothorax.  In addition, Joel explores endoscopic post-infarction VSD repair, 3D video-assisted endoscopic Dor procedure and MVR for post-infarction huge LV aneurysm, and non-cardioplegic myocardial protection for robotic mitral surgery. Before closing, Joel highlights upcoming events in CT surgery.    JANS Items Mentioned  1.) Outcomes of Re-Repair Versus Replacement After Failed Primary Mitral Regurgitation Repair: STS Adult Cardiac Surgery Database Analysis  2.) Minimally Invasive Thoracoscopically-Guided Right Minithoracotomy Versus Conventional Sternotomy for Mitral Valve Repair: The UK Mini Mitral Multicentre RCT  3.) One-Year Results of Novel Aortic Arch Hybrid Prosthesis for Repair of Acute DeBakey Type I Dissection With Malperfusion: PERSEVERE Study  4.) A Meta-Analysis of Efficacy and Safety of Parietal Pleurectomy Versus Pleural Abrasion in Treating Spontaneous Pneumothorax  CTSNet Content Mentioned  1.) Endoscopic Post-Infarction VSD Repair  2.) Pushing Surgical Boundaries: 3D Video-Assisted Endoscopic Dor Procedure and MVR for Post-Infarction Huge LV Aneurysm  3.) Non-Cardioplegic Myocardial Protection for Robotic Mitral Surgery  Other Items Mentioned  1.) Instructional Video Competition  2.) 2025 Endoscopic Cardiac Surgeons Club Video Competition  3.) 2025 CTSNet Recruitment Guide   4.) Career Center   5.) CTSNet Events Calendar  Disclaimer The information and views presented on CTSNet.org represent the views of the authors and contributors of the material and not of CTSNet. Please review our full disclaimer page here.

As usual in the final episode of the year, we hand out three awards for what we think are some of the finest pieces of information systems scholarship produced this year. Except that this time, we are live at the International Conference on Information Systems in Nashville, Tennessee, in a room packed with our listeners. While this means the quality of the audio of our recording is not so great, the quality of the papers we honor this year is. And with a room full of laughter celebrating great information systems scholarship, we end the year on a high note. Congratulations to Stefan, Christoph, and Jan for winning the Trailblazing Research Award, John and Prasanna for winning the Elegant Scholarship Award, and Yanzhen, Huaxia and Andrew for winning the Innovative Method Award 2025. References Lowry, M. R. L., Vance, A., & Vance, M. D. (2025). Inexpert Supervision: Field Evidence on Boards' Oversight of Cybersecurity. Management Science, https://doi.org/10.1287/mnsc.2023.04147. Porra, J., Hirschheim, R., Land, F., & Lyytinen, K. (2025). Seventy Years of Information Systems Development Methodologies from Early Business Computing to the Agile Era: A Two-part History. Part 1: From Pre to Early ISD Methodology Era: The Emergence of ISD Methodologies and Their Golden Era (1880–1980). Journal of Information Technology, 40(4), 441-469. Porra, J., Hirschheim, R., Land, F., & Lyytinen, K. (2025). Seventy Years of Information Systems Development Methodologies from Early Business Computing to the Agile Era: A Two-part History. Part 2: Later ISD to Early Post ISD Methodology Era: Adapting to Accelerated Context Expansion (1980–today). Journal of Information Technology, 40(4), 470-498. Abbasi, A., Somanchi, S., & Kelley, K. (2025). The Critical Challenge of using Large-scale Digital Experiment Platforms for Scientific Discovery. MIS Quarterly, 49(1), 1-28. Storey, V. C., Baskerville, R. L., & Kaul, M. (2025). Reliability in Design Science Research. Information Systems Journal, 35(3), 984-1014. Larsen, K. R., Lukyanenko, R., Mueller, R. M., Storey, V. C., Parsons, J., VanderMeer, D. E., & Hovorka, D. S. (2025). Validity in Design Science. MIS Quarterly, 49(4), 1267-1294. Vance, A., Eargle, D., Kirwan, C. B., Anderson, B. B., & Jenkins, J. L. (2025). The Fog of Warnings: How Non-Security-Related Notifications Diminish the Efficacy of Security Warnings. MIS Quarterly, 49(4), 1357–1384. Baiyere, A., Bauer, J. M., Constantiou, I., & Hardt, D. (2025). Fake News and True News Assessment: The Persuasive Effect of Discursive Evidence in Judging Veracity. MIS Quarterly, 49(3), 823-860. Seidel, S., Frick, C. J., & vom Brocke, J. (2025). Regulating Emerging Technologies: Prospective Sensemaking through Abstraction and Elaboration. MIS Quarterly, 49(1), 179-204. Burton-Jones, A., Boh, W., Oborn, E., & Padmanabhan, B. (2021). Advancing Research Transparency at MIS Quarterly: A Pluralistic Approach. MIS Quarterly, 45(2), iii-xviii. Horton, J. J., & Tambe, P. (2025). The Death of a Technical Skill. Information Systems Research, 36(3), 1799-1820. Chen, Y., Rui, H., & Whinston, A. B. (2025). Conversation Analytics: Can Machines Read Between the Lines in Real-Time Strategic Conversations? Information Systems Research, 36(1), 440-455. Grisold, T., Berente, N., & Seidel, S. (2025). Guardrails for Human-AI Ecologies: A Design Theory for Managing Norm-Based Coordination. MIS Quarterly, 49(4), 1239-1266. Clark, A. (2015). Surfing Uncertainty: Prediction, Action, and the Embodied Mind. Oxford University Press. Recker, J. (2021). Scientific Research in Information Systems: A Beginner's Guide (2nd ed.). Springer. Hirschheim, R., & Klein, H. K. (2012). A Glorious and Not-So-Short History of the Information Systems Field. Journal of the Association for Information Systems, 13(4), 188-235.

In episode 63 of Going anti-Viral, Dr Mari Kitahata joins host Dr Michael Saag to discuss the role of outcomes research on clinical decisions for patient care. Dr Kitahata is a Professor of Medicine at the University of Washington (UW) in the Division of Allergy and Infectious Diseases. For more than 3 decades, she has directed the UW/Fred Hutch Center for AIDS Research (CFAR) Clinical Research Core. Dr Kitahata's research focuses on improving long-term outcomes for people with HIV and she has led studies demonstrating key determinants of increased survival in people with HIV including early initiation of antiretroviral therapy and care managed by physicians with greater HIV experience. Dr Kitahata discusses the significance of outcomes research in clinical settings, particularly in the context of HIV care. She explains the differences between efficacy and effectiveness, the challenges faced in observational studies, and the importance of statistical techniques to address biases. Dr Kitahata and Dr Saag discuss the role of electronic medical records (EMRs) in enhancing data collection and the necessity of data validation through adjudication processes. Additionally, the conversation touches on the importance of patient-reported outcomes and the limitations of EMR data, including issues of misclassification. Finally, Dr Saag and Dr Kitahata discuss the distinction between predictive modeling and etiologic modeling in research, underscoring the complexities of clinical care and the future directions for outcomes research.0:00 – Introduction2:30 – Efficacy versus effectiveness5:51 – Challenges in outcomes research8:27 – Statistical techniques in observational studies16:13 – The role of electronic medical records19:36 – Patient-reported outcomes and their importance22:18 – Data validation and adjudication28:30 – Limitations of observational data35:08 – The future of outcomes research __________________________________________________Produced by IAS-USA, Going anti–Viral is a podcast for clinicians involved in research and care in HIV, its complications, and other viral infections. This podcast is intended as a technical source of information for specialists in this field, but anyone listening will enjoy learning more about the state of modern medicine around viral infections. Going anti-Viral's host is Dr Michael Saag, a physician, prominent HIV researcher at the University of Alabama at Birmingham, and volunteer IAS–USA board member. In most episodes, Dr Saag interviews an expert in infectious diseases or emerging pandemics about their area of specialty and current developments in the field. Other episodes are drawn from the IAS–USA vast catalogue of panel discussions, Dialogues, and other audio from various meetings and conferences. Email podcast@iasusa.org to send feedback, show suggestions, or questions to be answered on a later episode.Follow Going anti-Viral on: Apple Podcasts YouTubeXFacebookInstagram...

Summary This podcast episode features a comprehensive discussion with Dr. Ekama Carlson and Dr. Faranak Kamangar on the latest advancements in acne treatment, particularly focusing on energy-based devices and the innovative AvaClear laser. The speakers delve into the pathogenesis of acne, the effectiveness of various treatments, and the importance of patient selection for laser therapy. They also share insights from clinical trials and patient experiences, highlighting the transformative impact of these treatments on individuals suffering from acne. Takeaways - Acne affects 10% of the world's population, making it a significant dermatological issue. - Energy-based devices are becoming increasingly popular for managing acne. - Selecting the right patient for laser therapy is crucial for successful outcomes. - The Acne Laser Series protocol involves multiple treatments for optimal results. - AvaClear laser technology specifically targets sebaceous glands for effective acne treatment. - Clinical trials show promising results for the AvaClear laser in reducing inflammatory lesions. - Patient education about treatment expectations is essential for satisfaction. - Long-term outcomes of laser treatments can lead to significant improvements in skin health. - Innovations in dermatology are changing the landscape of acne treatment. - Combining treatments can enhance efficacy and patient satisfaction. Chapters 00:00 - Introduction to the Future of Dermatology Podcast 00:40 - Understanding Acne Pathogenesis and Treatments 01:52-  Energy-Based Devices for Acne Management 05:22 - Selecting Patients for Laser Therapy 06:40 - Acne Laser Series Protocol and Results 11:35 - Comparative Effectiveness of Treatments 15:05 - Innovations in Acne Treatment: The AvaClear Laser 19:18 - Clinical Trials and Efficacy of AvaClear 24:42 - Patient Experience and Long-Term Outcomes

Contributor: Meghan Hurley, MD Educational Pearls:  OTC Medications Dextromethorphan (DM) Most common OTC cough suppressant Minimal efficacy: Little evidence that it shortens the duration or severity of cough. Potential side effects: At recommended doses: Mild dizziness, drowsiness, GI symptoms Higher doses: Decreased consciousness, dissociative effects Guaifenesin Found in Mucinex and other severe cough/cold products Thins secretions and loosens mucus in airways No more effective than increasing oral fluid intake Prescription Medications Codeine-containing products Suppresses cough center in the medulla Metabolized via CYP2D6 with significant differences in metabolism between individuals: Low metabolizers experience little effect, high metabolizers have risk of increased toxicity Benzonatate (Tessalon Perles) Topical anesthetic; inhibits pulmonary stretch receptors and reduces cough reflex. Efficacy is mixed; no clear benefit over placebo. Precautions: do not bite or chew; dangerous in children

In this special episode of Skin Anarchy, Dr. Ekta Yadav sits down with supermodel, actress, podcaster, and YSE Beauty founder Molly Sims for an intimate conversation on how beauty evolves, how confidence is built, and how skincare becomes smarter with age. Known for her iconic presence and unfiltered approach on Lipstick on the Rim, Molly opens up about the real experiences that shaped her philosophy — from hormonal acne and melasma to rediscovering balance after years of harsh actives.Molly reflects on her earliest beauty memories, watching her mother turn daily routines into rituals that embodied strength and joy. That foundation, combined with her global modeling career, became its own education: effortless French skincare, British edge, Italian sensuality, and a universal truth — consistency beats extremes.Her journey to creating YSE Beauty began after her skin hit what she calls a “benefit plateau,” when aggressive ingredients stopped delivering results. She shares how shifting toward cushion actives, barrier support, and clinical but sensorial formulations transformed her skin and inspired a brand built on wisdom, simplicity, and results that feel good.For Molly, beauty isn't about correction or perfection — it's about alignment. It's the confidence that comes from choosing what serves you, whether that's a glow-inducing exfoliating pad, a subtle procedure, or simply giving your skin room to breathe.Listen to the full episode to hear Molly Sims discuss aging with intention, building YSE Beauty from the ground up, and why true luxury isn't the price tag — it's how you feel in your own skin.SHOP YSE Beauty and learn more on their social media!CHAPTERS:(0:03) - Introduction & Guest Welcome(1:07) - Early Beauty Memories & “It Girl” Origins(2:44) - Influences From Travel, Fashion & Global Beauty Culture(4:53) - Shifting Aesthetic Trends: From Harsh Treatments to Maintenance(6:59) - Social Media, Filler Culture & Confidence(9:46) - Personal Journeys With Procedures, Aging & Empowerment(12:11) - Why Wise Beauty Was Created(17:05) - Actives, Cushioning Ingredients & the Skin Plateau(21:52) - Luxury vs. Efficacy, Accessibility & Building a Smarter Beauty BrandPlease fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

In episode 550 of 'Coffee with Butterscotch,' the brothers take a hard look at online ads and why they rarely deliver the wishlist conversions indie devs hope for. They break down misleading metrics, misclicks, and the high cost of chasing visibility through paid channels. The conversation also gets into conventions and showcases, exploring why in-person events are great for networking and playtesting but often fall short as direct sales drivers. It's a grounded look at where marketing effort actually pays off and where it evaporates into thin air.Support How Many Dudes!Official Website: https://www.bscotch.net/games/how-many-dudesTrailer Teaser: https://www.youtube.com/watch?v=IgQM1SceEpISteam Wishlist: https://store.steampowered.com/app/3934270/How_Many_Dudes00:00 Cold Open00:12 Introduction and Welcome02:48 The Role of YouTube Shorts in Game Promotion05:32 Understanding Steam's Algorithm and Wishlist Dynamics08:44 Challenges of Scaling Marketing Efforts11:27 Exploring YouTube Ads and Their Effectiveness14:31 Evaluating the Impact of Advertising on Game Visibility19:54 Navigating Google Ads for Game Promotion22:51 Analyzing Click-Through Rates and Conversions26:07 The Efficacy of YouTube Ads29:45 The Illusion of Effective Advertising34:47 The Uncertainty of Marketing Outcomes41:47 Evaluating Events and Conventions43:09 Digital Events and Showcases45:39 The Challenge of Exclusivity in Marketing49:09 Understanding Randomness in Game Promotion51:45 The Cost-Effectiveness of Marketing Approaches55:02 Balancing Development and Marketing EffortsTo stay up to date with all of our buttery goodness subscribe to the podcast on Apple podcasts (apple.co/1LxNEnk) or wherever you get your audio goodness. If you want to get more involved in the Butterscotch community, hop into our DISCORD server at discord.gg/bscotch and say hello! Submit questions at https://www.bscotch.net/podcast, disclose all of your secrets to podcast@bscotch.net, and send letters, gifts, and tasty treats to https://bit.ly/bscotchmailbox. Finally, if you'd like to support the show and buy some coffee FOR Butterscotch, head over to https://moneygrab.bscotch.net. ★ Support this podcast ★

Show SummaryOn today's episode, we're featuring a conversation with Navy spouse Mackenzie Yaede, family communications and logistics coordinator for Luke's Wings, an organization that provides emergency travel planning services and airplane tickets for the families and loved ones of wounded, ill, and injured service members, Veterans, and fallen officers, during hospital recovery and rehabilitation.Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestMackenzie Yaede serves as the Family Communications and Logistics Coordinator at Luke's Wings, where she manages the day-to-day operations of the organization's flight assistance programs for wounded warriors, Veterans, fallen officers, and their families. In this role, she reviews and approves flight requests, coordinates with travel partners, supports program reporting, and collaborates with partner organizations—including military hospitals, hospice care centers, and law enforcement agencies—to ensure seamless and compassionate support for those in need.Before joining Luke's Wings, Mackenzie spent several years working in the field of education, where she built a strong foundation in program coordination, student support, and inclusive practices. Most recently, she served as an Education Specialist, leading special education assessments, facilitating individualized education plans (IEPs), and supporting cross-functional teams to promote academic and behavioral growth. Her prior roles in both New Jersey and California focused on delivering targeted interventions, collaborating with families, and fostering equitable, student-centered environments.In addition to her professional work, Mackenzie brings extensive volunteer leadership experience, particularly in support of military families and individuals with special needs. For the last several years, she has overseen key aspects of an annual family camp that supports individuals with disabilities and their caregivers, coordinating inclusive programming and providing meaningful respite and community. While living in San Diego, she also founded and led a military ministry support group at her local parish, offering fellowship and support for military-connected individuals. Her broader volunteer work includes mentoring youth, coordinating service projects, and supporting faith-based outreach programs.As a military spouse with a deep personal connection to the military community and a lifelong passion for service, Mackenzie is proud to support Luke's Wings' mission of keeping families connected during times of healing and recovery. She understands firsthand the power of family presence and is honored to play a role in reuniting loved ones when they are needed most.Links Mentioned During the EpisodeLuke's Wings WebsiteDelta Sky Miles ContributionPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is The PsychArmor learning path, Self-Care for Caregivers. Learn how you can prevent burnout and care for yourself throughout your caregiving journey. After completing all of the courses in this series, you'll receive a "Self-care for Caregivers" digital badge to share on social media and highlight your learning journey. You can find the resource here:  https://learn.psycharmor.org/bundles/self-care-for-caregivers Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

SummaryIn this conversation, Kimberly interviews best selling author Rachelle Robinette and they discuss the transformative power of herbalism, exploring various herbs for sleep, emotional balance, and hormonal health. They emphasize the importance of food as medicine, the nuances of herb-drug interactions, and the significance of cycling herbs. Rachelle shares personal stories and insights on how herbalism can be integrated into modern life, highlighting the role of bitters in digestion and the holistic approach to health.Sponsors: LMNTOFFER: Right now, for my listeners LMNT is offering a free sample pack with any LMNT drink mix purchase at DrinkLMNT.com/FEELGOOD. That's 8 single serving packets FREE with any LMNT any LMNT drink mix purchase. This deal is only available through my link so. Also try the new LMNT Sparkling — a bold, 16-ounce can of sparkling electrolyte water.USE LINK: DrinkLMNT.com/FEELGOODGLOWING GREENS POWDER OFFER: Go to mysolluna.com and use the CODE: PODFAM15 for 15% off your entire order. USE LINK: mysolluna.com CODE: PODFAM15 for 15% off your entire order. Rachelle Robinette Resources: Website: rachellerobinett.comBook: Naturally, The Herbalist's Guide to Health and TransformationSocial: @rachellerobinettChapters00:00 Introduction to Herbalism02:43 Food as Medicine05:58 Holistic Approach to Health09:01 Efficacy of Herbal Remedies12:03 Cycling and Dependency on Herbs16:15 Exploring Safe Sleep Herbs19:07 Herbs and Autoimmune Conditions22:13 Addressing Brain Fog with Herbalism25:14 The Power of Herbal Combinations28:06 Daily Herbal Practices and Personal Preferences31:11 Heart-Opening Herbs and Emotional Healing34:14 Grounding Herbs for Modern Life37:15 Herbs for Fertility and Hormonal Balance40:18 Bitters and Digestive Health43:08 The Role of the Liver in Hormonal Balance46:09 The Importance of Enjoyable HerbalismSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Major health organizations, including the CDC and ACOG, recommend universal Hepatitis C Virus (HCV) screening for all pregnant women during each pregnancy and at time of delivery. Ideally, pregnant women should be screened for hepatitis C virus infection at the first prenatal visit of each pregnancy. If the antibody screen result is positive, hepatitis C virus RNA polymerase chain reaction testing is done to confirm the diagnosis. The risk of perinatal transmission of HCV is up to 9%, with at least one-third of transmissions occurring antenatally. While antiviral therapy is recommended for Hepatitis B in pregnancy with a viral load greater than 200,000 international units/mL to decrease the risk of vertical transmission, the same is not the case for Hep C. According to the ACOG CPG #6 from September 2023, there are no standard treatment protocols for Hep C in pregnancy but a new publication from the PINK journal (7 Dec 2025) is calling for a change. That new publication is, “Hepatitis C Treatment During Pregnancy: Time for a Practice Change”. Listen in for details. 1. ACOG CPG #6; Sept 20262. Bhattacharya D, Aronsohn A, Price J, Lo Re V. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America. 2023;:ciad319. doi:10.1093/cid/ciad319.3. Chappell CA, Kiser JJ, Brooks KM, et al. Sofosbuvir/¬Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2025;80(4):744-751. doi:10.1093/cid/ciae595.4. Reau N, Munoz SJ, Schiano T. Liver Disease During Pregnancy. The American Journal of Gastroenterology. 2022;117(10S):44-52. doi:10.14309/ajg.0000000000001960.5. Dutra, Karley et al. Hepatitis C Treatment During Pregnancy: Time for a Practice Change. American Journal of Obstetrics & Gynecology MFM, Volume 0, Issue 0, 1018656. Society for Maternal-Fetal Medicine Consult Series #56: Hepatitis C in Pregnancy-Updated Guidelines: Replaces Consult Number 43, November 2017. Society for Maternal-Fetal Medicine (SMFM). Electronic address: pubs@smfm.org, Dotters-Katz SK, Kuller JA, Hughes BL. American Journal of Obstetrics and Gynecology. 2021;225(3):B8-B18. doi:10.1016/j.ajog.2021.06.008

In this episode, we review the pharmacology, indications, adverse effects, and unique drug characteristics of 5-HT3 receptor antagonists such as ondansetron (Zofran) and palonosetron (Aloxi). Key Concepts There are four 5-HT3 (serotonin subtype 3) receptor antagonists on the market: ondansetron, granisetron, dolasetron, and palonosetron. These have primarily been studied for acute chemotherapy-induced nausea and vomiting (within 24 hours of chemotherapy administration) and for post-operative nausea and vomiting. When used for chemotherapy-induced nausea/vomiting, 5-HT3 receptor antagonists are given prior to chemotherapy (usually 30-60 minutes before) on day #1. They are not given on subsequent days because they are not as effective for delayed nausea and vomiting. Palonosetron has the longest half-life, longer binding affinity to the 5-HT3 receptor, and trends towards having the best efficacy among the 5-HT3 receptor antagonists. 5-HT3 receptor antagonists are associated with QTc prolongation and may cause headache, dizziness, constipation, or diarrhea. Their association with an increased risk of serotonin syndrome is controversial and not supported from a mechanistic perspective. References Simino GP, Marra LP, Andrade EI, et al. Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2016;9(9):1183-1194. doi:10.1080/17512433.2016.1190271 Tricco AC, Soobiah C, Blondal E, et al. Comparative efficacy of serotonin (5-HT3) receptor antagonists in patients undergoing surgery: a systematic review and network meta-analysis. BMC Med. 2015;13:136. Published 2015 Jun 18. doi:10.1186/s12916-015-0371-y Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol. 2020;38(24):2782-2797. doi:10.1200/JCO.20.01296 Herrstedt J, Clark-Snow R, Ruhlmann CH, et al. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting. ESMO Open. 2024;9(2):102195. doi:10.1016/j.esmoop.2023.102195 Rojas-Fernandez CH. Can 5-HT3 Antagonists Really Contribute to Serotonin Toxicity? A Call for Clarity and Pharmacological Law and Order. Drugs Real World Outcomes. 2014;1(1):3-5. doi:10.1007/s40801-014-0004-3 Li WS, van der Velden JM, Ganesh V, et al. Prophylaxis of radiation-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med. 2017;6(2):104-117. doi:10.21037/apm.2016.12.01

For those asking, here is the overdue podcast release of my debate with Mark Cuban on Covid mandates. We've been aggressively prioritizing promotion of your YouTube channel this past month — something we haven't done before — and we unfortunately got behind on posting on podcast platforms. Moving forward, this will not be an issue. Enjoy the debate if you'd like to listen while driving or doing other activities! SummaryIn this conversation, Mark and I engage in a fiery debate about the COVID-19 pandemic, vaccine mandates, and the implications of free speech in academia. We explore the complexities of public health decisions, the perceived biases in academic discourse, and the evolving understanding of vaccine efficacy and safety. Mark defends the necessity of vaccine mandates for protecting public health, while I raise concerns about the adverse effects and the risk-benefit analysis for young people.—Spotify linkApple link(also available on Overcast and other platforms)—Chapters00:00 Diversity in Hiring: Merit vs. Representation21:11 The Efficacy of Vaccines and Community Health27:10 Vaccine Policies Across Europe33:19 Community Responsibility and Vaccination39:12 Myocarditis Risks and Vaccine Decisions47:06 Accountability for Vaccine Mandates52:40 Understanding Myocarditis Risks: Infection vs. Vaccine58:42 The Role of Comorbidities in COVID Outcomes01:04:01 Analyzing Risk: Vaccination vs. Natural Infection01:09:52 Community Benefit vs. Individual Risk in Vaccination—The Illusion of Consensus is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber: This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.illusionconsensus.com/subscribe

Featuring an interview with Dr Priyanka Sharma, including the following topics: Endocrine therapy for hormone receptor-positive, HER2-negative high-risk localized breast cancer (0:00) Johnston SR et al. monarchE: Primary overall survival (OS) results of adjuvant abemaciclib + endocrine therapy (ET) for HR+, HER2-, high-risk early breast cancer (EBC). ESMO 2025;Abstract LBA13. Durvalumab in combination with neoadjuvant chemotherapy for localized triple-negative breast cancer (TNBC) (3:25) Loibl S et al. Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC) – Long-term analysis from the GeparNuevo trial. ESMO 2025;Abstract 292MO.  Efficacy and safety findings with TROP2-directed antibody-drug conjugates for metastatic TNBC (5:11) Cortés JC et al. Primary results from ASCENT-03: A randomized phase III study of sacituzumab govitecan (SG) vs chemotherapy (chemo) in patients (pts) with previously untreated advanced triple-negative breast cancer (TNBC) who are unable to receive PD-(L)1 inhibitors (PD-[L]1i). ESMO 2025;Abstract LBA20.  de Azambuja E et al. Patient-reported outcomes (PROs) with sacituzumab govitecan (SG) + pembrolizumab (pembro) vs chemotherapy (chemo) + pembro in patients (pts) with previously untreated PD-L1+ metastatic triple-negative breast cancer (mTNBC) in the phase III ASCENT-04/KEYNOTE-D19 study. ESMO 2025;Abstract LBA22.  Dent R et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) vs chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) for whom immunotherapy was not an option: Primary results from the randomised, phase III TROPION-Breast02 trial. ESMO 2025;Abstract LBA21.  CME information and select publications

Auch in Jahr sechs nach Beginn der Corona-Pandemie leiden Hunderttausende an Long Covid. Welche Erklärungen und Therapien gibt es mittlerweile? 1,5 Millionen Menschen in Deutschland leiden einer Schätzung der ME/CFS Foundation zufolge an schwerem Long Covid oder ME/CFS. Doch noch immer mangelt es an wirksamen Therapien - und an ausreichender Versorgung. Viele Betroffene pilgern von einer Praxis zur nächsten, die meisten müssen die Behandlungen aus eigener Tasche bezahlen. Denn das Krankheitsbild ist divers, es gibt mehr als 200 Symptome. Und es sind ganz verschiedene Mechanismen, die die Menschen so krank machen. Was weiß man heute? Wie entsteht Long Covid? Welche Wege führen zu einer besseren Versorgung? Und welche erfolgversprechenden Therapieansätze gibt es? Darüber spricht Wissenschaftsredakteurin Korinna Hennig in einer Live-Podcastfolge aus dem Haus der Wissenschaft in Braunschweig mit Experten. Mit dabei: Der Infektionsbiologe Dieter Jahn (TU Braunschweig) und die Hausärztin Susanne Fröhlich aus Isernhagen. HINTERGRUNDINFORMATIONEN: Studie zu Immunadsorption: Stein, E. et al.: Efficacy of repeated immunoadsorption in patients with post-COVID myalgic encephalomyelitis/chronic fatigue syndrome and elevated β2-adrenergic receptor autoantibodies: a prospective cohort study-The Lancet Regional Health Europe 2024. https://pubmed.ncbi.nlm.nih.gov/39759581/#:~:text=Interpretation%3A%20Immunoadsorption%20may%20improve%20symptoms,function%20in%20the%20condition%27s%20pathophysiology Studie zu hyperbarer Sauerstofftherapie: Kjellberg, A. et al.: Ten sessions of hyperbaric oxygen versus sham treatment in patients with long covid (HOT-LoCO): a randomised, placebo-controlled, double-blind, phase II trial. BMJ Open 2025. https://pubmed.ncbi.nlm.nih.gov/40228859/ Studie zu HELP-Apherese/Blutwäsche: Espana-Cueto, Sergio et al: Plasma exchange therapy for the post COVID-19 condition: a phase II, double-blind, placebo-controlled, randomized trial. Nature Communications 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11850642/ Links zu der Doppelfolge der "Science Cops" zu Long Covid: https://www.ardaudiothek.de/episode/urn:ard:episode:f2e192241785f729/ https://www.ardaudiothek.de/episode/urn:ard:episode:cee04aafe360636e/ Link zu "Deep Science" vom Deutschlandfunk: https://www.ardaudiothek.de/sendung/deep-science/urn:ard:show:498714386e4aad63/ Hier geht's zum Podcast ARD Klima Update: https://1.ard.de/ARD_Klima_Update?cp=synapsen Hier geht's zur Synapsenseite: https://www.ndr.de/nachrichten/podcastsynapsen100.html Hier geht's zu ARD Gesund: https://www.ndr.de/ratgeber/gesundheit Habt ihr Feedback oder einen Lifehack aus der Welt der Wissenschaft? Schreibt uns gerne an synapsen@ndr.de.

In this episode Ed interviews Dr. Mark Hoddle of University of California Riverside. They discuss some of Mark's worldly adventures while trying to track down biological control agents and his work with the South American palm weevil. Additional Resources Entomology's Indiana Jones Biocontrol lab Center for Invasive Species South American Palm Weevil Time Stamps (01:08:56) Flight Capacity and Energy Dynamics (01:10:23) Analyzing Flight Patterns and Dispersal (01:11:51) Implications of Dispersal Patterns (01:13:55) Urban Environments and Invasive Species (01:15:39) Host Preferences and Economic Impact (01:17:30) Management Strategies for Invasive Weevils (01:19:56) Innovative Control Methods in Agriculture (01:22:01) Economic Considerations in Pest Management (01:24:25) Trapping and Monitoring Techniques (01:27:17) Attract and Kill Strategies (01:30:09) Field Trials and Efficacy of Treatments (01:38:26) Proactive Management of Invasive Pests (01:42:01) Proactive Approaches to Invasive Pests (01:51:44) Biological Control Innovations (01:59:42) Future of Invasive Species Management (02:06:52) Public Awareness and Invasive Species (02:12:22) Closing Thoughts and Resources Zaworski, E. (Host) Hoddle, M. (Interviewee). S4:E42 (Podcast). The Bug Crusade: Adventures of the Indiana Jones of Entomology Part 2. 12/3/2025. In I See Dead Plants. Crop Protection Network.   Transcript

Show Summarywith Lesa Shaw, an experienced Indigenous consultant and community leader with more than 30 years of service across Tribal, federal, state, and municipal sectors. Lesa and I talk about PsychArmor's effort to develop training materials through their effort supporting Native American and Alaska Native Veterans and Service Members. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestLesa Shaw is a tribal leader, public-health consultant, and advocate dedicated to improving health outcomes for Native and Tribal communities, especially Native American veterans. She holds a Master of Public Administration degree from the University of Oklahoma. Over her career, Lesa has held multiple roles across federal, state, tribal, and local government. She has served as a contracting officer and practice manager with the Indian Health Service, worked as a health-policy analyst for tribes, and served as a municipal-level elected official in the city of Shawnee at the request of the central tribes. In tribal service, Lesa has worked to bridge cultural traditions and modern health policy — advocating for culturally respectful care that honors tribal identity and heritage while addressing systemic inequalities in access to care. More recently, she has been part of the advisory committee of PsychArmor 's Native American & Alaska Native Veterans Health & Wellness initiative — helping guide efforts to make veteran care more culturally informed and supportive of Native and Tribal peoples. Lesa remains deeply committed to amplifying the voices of Native veterans and their families, building trust between tribal communities and federal care systems, and laying the groundwork for long-term, culturally grounded health equity.Links Mentioned During the EpisodeBTM214 – Dr. Melita “Chepa” RankBTM 220 – CSM(R) Julia KellyBTM222 – Dean DauphinaisPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course course Understanding the VA for Caregivers. This course helps caregivers navigate and better utilize the services of the VA – the largest integrated healthcare system in the country. The content for this course was developed collaboratively with a working group of various VA Departments. You can find the resource here:  https://learn.psycharmor.org/courses/understanding-the-va-for-caregivers-2 Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

"We bring our patterns with us wherever we go, into every relationship, and we necessarily and inevitably bring them into the therapy relationship or the psychoanalytic relationship, because that's a relationship too. It's not a matter of choice. It simply happens. It happens everywhere. The therapist doesn't do anything to make it happen. This is the human condition. We bring our patterns. The thing that makes psychotherapy, psychotherapy, and not just another relationship, is that we do something different. What we do that's different is, instead of just repeating our same old patterns with a new person, we create the conditions where it becomes possible to notice the patterns, to recognize them, to put words to them, and understand them and discuss them. Out of that experience and that understanding comes the freedom to do things differently, to not have to repeat the same patterns. I always make a point, is that true for everyone? Does everybody need therapy? Well, everybody repeats earlier characteristic patterns. For some people, those patterns allow you to live a satisfying and rewarding life, with pleasure and connection and meaning and intimacy. So if that's the case, you're still repeating early patterns, but that's what it means to be human. However,  some people are living out patterns that cause distress or limitation, that get in the way of living the life they could lead, and that's what we work with in psychotherapy and psychoanalysis." Episode Description: We begin our conversation on the importance of communicating our basic concepts in jargon-free language. Jonathan shares with us the limitations he finds in academic psychology, where analytic ideas are meaningfully misunderstood. We work our way through his paper discussing 'unconscious mental life', the 'mind in conflict', 'disavowal' (instead of 'repression') and 'psychic continuity' (instead of 'psychic determinism') to name but a few of the topics we cover. We recognize the analytic opportunity to discover the ways that we live in the childhood 'then' as opposed to the novel 'now'. Jonathan presents clinical material to demonstrate these concepts, including his own 'disavowal' as he began his analysis. We close with an appreciation of the importance of one's own affective discovery of these otherwise unconscious forces. I also note Jonathan's passion and clarity about our work.   Our Guest: Jonathan Shedler, PhD is an author, consultant, and teacher. His article The Efficacy of Psychodynamic Psychotherapy helped establish psychoanalytic therapy as an evidence-based treatment. He's the author of over 100 scholarly articles, creator of the Shedler-Westen Assessment Procedure (SWAP) for personality diagnosis and case formulation, and co-author of the Psychodynamic Diagnostic Manual. He is Clinical Professor of Psychiatry at UCSF and a Training and Supervising Analyst at the San Francisco Center for Psychoanalysis. Follow Jonathan at: https://jonathanshedler.substack.com/.   Recommended Readings: Schopenhauer's Porcupines by Deborah Luepnitz offers a series of case studies that read like short stories. They will give you a "feel" for what goes on in the clinical consulting room & in the mind of the clinician.   Psychoanalytic Psychotherapy: A Practitioner's Guide by Nancy McWilliams offers a readable introduction to psychodynamic concepts and thinking.    Freud and Man's Soul by Bruno Bettelheim offers real insight into the origins of psychoanalytic theory and how and why it is personally relevant to everyone.    Therapeutic Communication by Paul Wachtel offers answers to the perennial clinician question, "What do I say and how do I say it?"   Long-term Psychodynamic Psychotherapy by Glen Gabbard is the closest thing to a comprehensive course in doing psychodynamic therapy.  Introduction to the Practice of Psychoanalytic Psychotherapy by Alessandra Lema

Today, I am delighted to be joined by a friend and colleague, Mike Mutzel.  Mike has a master's in Clinical Nutrition from the University of Bridgeport. He is a graduate of the IFM, applies functional medicine in clinical practice, and is a consultant lecturer who teaches leading-edge science in a concise format for progressive clinicians to prevent chronic diseases.  In our discussion, Mike and I unpack the benefits of creatine monohydrate, highlighting the importance of ensuring the products we use are free of impurities. We explain how creatine monohydrate gets created, answer many listener questions, and describe current research specific to creatine monohydrate, discussing ways to support bone health, navigate dosing, and how to troubleshoot.  This conversation with Mike Mutzel is truly invaluable, and I look forward to having him back on the podcast to dive a little deeper into the science.  IN THIS EPISODE, YOU WILL LEARN: How creatine supports energy production across muscles, the brain, and other organ systems Why vegetarians and vegans should take creatine What to consider when choosing high-quality creatine supplements Dosing strategies based on diet, exercise, sleep, and individual needs How taking creatine with electrolytes while exercising can improve absorption Benefits of supplementing with amino acids alongside creatine for illness, recovery, or when protein intake is low Adjusting your creatine dosage for sleep, travel, or exercise demands How creatine supports bone and muscle health  The value of creatine for the eyes and ears Connect with Cynthia Thurlow   Follow on X, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Mike Mutzel On his website YouTube Instagram High Intensity Health Podcast Creatine Research: Creatine in Women's Health: Bridging the Gap From Menstruation Through Pregnancy to Menopause Effects of Creatine and Resistance Training on Bone Health in Postmenopausal Women Creatine Supplementation (3 g/d) and Bone Health in Older Women: A 2-Year, Randomized, Placebo-Controlled Trial Creatine Supplementation in Depression: A Review of Mechanisms, Efficacy, Clinical Outcomes, and Future Directions The Effects of 8-Week Creatine Hydrochloride and Creatine Ethyl Ester Supplementation on Cognition, Clinical Outcomes, and Brain Creatine Levels in Perimenopausal and Menopausal Women (CONCRET-MENOPA): A Randomized Controlled Trial

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Cassie Kline, MD, MAS, about updated efficacy data from the phase 2 FIREFLY-1 study (NCT04775485) of tovorafenib (Ojemda) in patients with relapsed/refractory pediatric low-grade glioma (pLGG) that were presented at the 2025 Society of Neuro-Oncology Annual Meeting. Dr Kline is an attending physician and director of Clinical Research in the Department of Neuro-Oncology at Children's Hospital of Philadelphia in Pennsylvania. In our exclusive interview, Dr Kline discussed longer-term efficacy and safety data from the trial, noting the sustained response rates, continued tumor shrinkage, and rates of patients who remained treatment free after approximately 36 months of follow-up. _____ That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters. OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn. If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us! Thanks again for listening to OncLive On Air. *OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn. This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he will review two papers. The first paper, by Hernández-Hernández et al. looks at clinical and demographic factors associated with UPA treatment persistence and assesses how cardiovascular risk minimization measures have impacted UPA prescription patterns. The second paper by Nozaki et al. evaluates the clinical efficacy and continuation rates of JAK inhibitors and TNF inhibitors in RA patients with poor prognosis factors.

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

This week primary care physicians Gary, Henry, Kate and Mark discuss the safety of CBD, a new guideline for managing adults with hypertension, whether COVID-19 vaccines are still effective, and a living guideline from the BMJ to help us choose the best diabetes drugs. Links to stuffEssential Evidence Plus Illinois Academy of Family Physicians meeting Dec 6 in Naperville, IL (Kate, Gary and Mark)   North Dakota Academy of Family Physicians Big Sky Conference Jan 19 in Big Sky, Montana (Gary and Kate) Safety of CBDACC/AHA Hypertension guidelinePREVENT-CVD risk calculatorEfficacy of COVID-19 vaccinesBMJ living guideline for diabetesBMJ MATCH-IT interactive tool for selecting drugs

Dr. Rosensweet graduated from the University of Michigan Medical School in 1968. Since 1971, he has been in private medical practice, with offices in Florida, New Mexico, California, and Colorado. Early in his career, Dr. Rosensweet trained the first nurse practitioners in the United States and was in charge of health promotion for the State of New Mexico.He is a nationally known lecturer and presenter at The American Academy of Anti-Aging Medicine (A4M), The American College for Advancement in Medicine (ACAM), The Age Management Medicine Group (AMMG), and more. In 2019, he was called to Washington to speak in front of The National Academies of Science Engineering and Medicine (NASEM) on “The Safety and Efficacy of Bioidentical Hormones.”Dr. R is the Founder of The Menopause Method and The Institute of BioIdentical Medicine, where he has been training medical professionals to master cBHRT using the most advanced and modern tools. His protocol has been used to treat more than 12,000 women. More about Dr. Rosensweet:* Was recently named one of “The Biggest Names in Anti-Aging Medicine” by The American Academy of Anti-Aging Medicine (A4M)* Author of the books, Menopause and Natural Hormones and Happy Healthy Hormones: How to Thrive in Menopause* Founder of Brite (www.brite.live) and I Wonder, Doctor… (www.iwonderdoctor.com)* Founder and co-chair of the Coalition to Protect Compounded Bioidentical Hormones (cbhrtcoalition.org)*Organizer of a National Summit Committee on the Treatment of Women in Menopause with Bioidentical Hormones* Principal Investigator for a scientific study of female hormones.https://brite.live/       https://iobim.org       https://www.davedrosensweetmd.comhttps://www.facebook.com/share/g/1CEpiqShxB/https://www.instagram.com/menopausedoctor?utm_source=ig_web_button_share_sheet&i“I recommend this product to my clients for hemorrhoids, fissures, itching, irritation, dryness and for any kind of butt drama. I like it because it's all-natural, soothing, effective, multi-purpose and female founded. It's made with healing ingredients such as arnica, vitamin e oil, organic aloe and the branding speaks for itself.” Use code VAGINACOACH to save 20% at www.anythingbrands.comThank you so much for listening! I use fitness and movement to help women prevent and overcome pelvic floor challenges like incontinence and organ prolapse. There is help for women in all life stages! Every Woman Needs A Vagina Coach! Please make sure to LEAVE A REVIEW and SUBSCRIBE to the show for the best fitness and wellness advice south of your belly button. *******************I recommend checking out my comprehensive pelvic health education and fitness programs on my Buff Muff AppYou can also join my next 28 Day Buff Muff Challenge https://www.vaginacoach.com/buffmuffIf you are feeling social you can connect with me… On Facebook https://www.facebook.com/VagCoachOn Instagram https://www.instagram.com/vaginacoach/On Twitter https://twitter.com/VaginaCoachOn The Web www.vaginacoach.comGet your Feel Amazing Vaginal Moisturizer Here

Delanie Fischer chats with Jack R. Bialik, technologist and author of Lost in Time: Our Forgotten and Vanishing Knowledge, to explore the mind-bending question: If only a fraction of history is recorded, what has been lost that we're rediscovering—and what has been lost forever? From ancient medical breakthroughs to engineering feats that outperform our modern technology, this episode dives into the forgotten brilliance of past civilizations, the cycles of destruction, and what these revelations mean for us as a society and personally. Episode Highlights:  The Process and Efficacy of Cranial and Cataract Surgery as Early as 800 BC 2010 BC Swords That Are Still Sharp (Plus a New, Old Discovery) An Ancient Battery, Roman Vending Machine, and Superior Concrete Disposal and Sanitation Solutions That Rival and Surpass Modern Systems How Do We Know If We're Interpreting Artifacts Correctly? The Secrets of the Pyramids: Calculations and Construction Theories The Cycle of Destruction and What Could Wipe Out Modern Knowledge What Knowledge of Ours Might Survive a Civilizational Collapse? Wise Practices to Reclaim for Sustainable Living and Preservation What's Stood the Test of Time: Materials, Tools, and Concepts That Endure ⁠CozyEarth.com ⁠- Right now, you can stack my code HELPLESS on top of their sitewide sale - giving you up to 40% off in savings. ____ A quick 5-star rating means so much! ⁠https://podcasts.apple.com/us/podcast/self-helpless/id1251196416⁠ Free goodies like The Quote Buffet + The Watch & Read List: ⁠https://www.selfhelplesspodcast.com/⁠ Ad-free episodes on ⁠Patreon: https://www.patreon.com/selfhelpless⁠ Your Host, Delanie Fischer:⁠ https://www.delaniefischer.com⁠ ____ Related Episodes: 20 Documentaries To Watch This Year: https://www.delaniefischer.com/selfhelplesspodcast/episode/2542cab6/self-helpless-snack-whats-your-favorite-documentary-20-documentaries-to-watch-this-year AI, Robotics, and The Future of Work and Life with Dr. Catie Cuan: https://www.delaniefischer.com/selfhelplesspodcast/episode/2458ba1f/ai-robotics-and-the-future-of-work-and-life-with-dr-catie-cuan The Future of Mental Health and Medicine: Psychedelic Therapy, Technology, and Ancient Healing with Dr. Dave Rabin: https://www.delaniefischer.com/selfhelplesspodcast/episode/f08920eb/the-future-of-mental-health-and-medicine-psychedelic-therapy-technology-and-ancient-healing-with-dr-dave-rabin Learn more about your ad choices. Visit megaphone.fm/adchoices

Show SummaryOn today's episode, we're featuring a conversation with Bob Delaney, a mental health advocate who has also had a full life: a college basketball player, a new jersey state trooper who went undercover in some of the biggest Mob families in new jersey, and his role as a high-profile NBA referee. Bob's insights have been sought after by senior military leadership to speak to troops about mental health and posttraumatic stress. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestBob Delaney is an NBA Cares Ambassador and the Southeastern Conference (SEC) Special Advisor for Officiating Development. He served as the NBA's Vice President of Referee Operations and Director of Officials, after 25 seasons as an NBA referee. Prior to his career in professional basketball, Delaney was a highly decorated New Jersey State Trooper who went undercover to infiltrate the mafia; causing his post-traumatic stress journey. Delaney's firsthand experiences coupled with a passion to better understand mental health make him an expert on the subject. His efforts to educate and bring attention to the topic of post-traumatic stress have entailed visits to military troops around the world, including multiple trips to Afghanistan and Iraq. Described by retired General Robert Brown, U.S. Army Four Star Commander of the Pacific, as the "person who related to soldiers better than any visitor I have seen in my 36 years in the military," Delaney authored a book on the topic, Surviving the Shadows: A Journey of Hope into Post Traumatic Stress. He is also the author of Covert: My Life Infiltrating the Mob. His most recent book - Heroes are Human...Lessons in Resilience, Courage and Wisdom from the COVID Frontlines shares the emotional toll on our healthcare community as they fought an invisible enemy. He has been the subject of numerous media articles and shows including Dr. Sanjay Gupta CNN. Delaney is with the University South Florida Corporate Training and Professional Education Office as Lead Instructor for Trauma Awareness, Resilience, Selfcare programs.Links Mentioned During the EpisodeBob Delaney's Web sitePsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course course Understanding the VA for Caregivers. This course helps caregivers navigate and better utilize the services of the VA – the largest integrated healthcare system in the country. The content for this course was developed collaboratively with a working group of various VA Departments. You can find the resource here:  https://learn.psycharmor.org/courses/understanding-the-va-for-caregivers-2 Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In this bonus episode of The Alan Sanders Show, we dive into the shocking announcement of Marjorie Taylor Greene resigning from Congress, Justice Samuel Alito's emergency stay blocking a Texas redistricting order and bombshell new data showing flu vaccines with negative efficacy. Then we switch gears for Thanksgiving food talk with guest Valerie Holt. Alan then alludes to the true story of William Bradford and the Pilgrims' first Thanksgiving that you won't hear in school. Then we close with the Vulcan Mind-meld segment with guest BK from BK on the Air. Please take a moment to rate and review the show and then share the episode on social media. You can find me on Facebook, X, Instagram, GETTR,  TRUTH Social and YouTube by searching for The Alan Sanders Show. And, consider becoming a sponsor of the show by visiting my Patreon page!

Fear of virologic failure is a major barrier to ensuring that people living with virally suppressed HIV are receiving the most optimal antiretroviral therapy (ART) regimen for them. Stream this Medical Minute to learn more about key guideline recommendations regarding ART switch and reassuring clinical data regarding efficacy, tolerability, and quality of life associated with switching a suppressive ART regimen. Topics covered include:Efficacy of switching to 2-drug oral ART: real-world evidenceReal-world analyses of virologic failure with switch to long-acting cabotegravir plus rilpivirinePatient selection to reduce risk of virologic failure with switch Regimen-specific switch considerationsPresenters:Dima Dandachi, MD, MPH, FIDSA, FACPAssociate Professor of MedicineDivision of Infectious DiseasesUniversity of MissouriMedical DirectorHIV Treatment and Prevention Program, MUHCMedical DirectorBoone County Public Health and Human ServicesColumbia, MissouriChloe Orkin, MBChB, FRCP, MDProfessor of Infection and InequitiesDean for Healthcare TransformationQueen Mary University of LondonFaculty of Medicine and DentistryHonorary Consultant PhysicianBarts Health NHS TrustLondon, United KingdomLink to full program and accompanying slides:https://bit.ly/3KPN0xbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode of The Smart Human Podcast, host Aly welcomes Dr. Robin Mesnage, a toxicologist and research fellow at King's College London, to discuss the toxicology and pharmacology of glyphosate, commonly known as Roundup. The conversation delves into the effects of glyphosate on the microbiome and cellular health, vulnerable periods of exposure, and ways to reduce exposure. Dr. Mesnage also shares insights from a significant 2025 rat study highlighting the carcinogenicity of glyphosate. The discussion extends to the broader implications of pesticide use on human health, food safety, and agricultural practices. Practical tips for reducing exposure to glyphosate and other chemicals at home are also provided. 00:00 Introduction to the Smart Human Podcast 00:50 Meet Dr. Robin Mesnage: Toxicologist and Research Fellow 01:31 Groundbreaking Glyphosate Study 02:27 Study Design and Findings 03:36 Implications of Glyphosate on Human Health 10:20 Glyphosate in Agriculture and Its Widespread Use 17:04 Glyphosate's Impact on the Gut Microbiome 20:58 Daily Exposure to Glyphosate 24:06 Protecting Vulnerable Populations 26:21 Environmental and Airborne Exposure 29:33 The Glyphosate Controversy: Legal Battles and Health Concerns 32:34 The Impact of Glyphosate on Agriculture and Sustainability 36:24 Organic Farming and Certification Standards 39:14 Practical Tips to Reduce Glyphosate Exposure 51:59 The Importance of Healthy Lifestyle and Vulnerable Populations 53:54 Conclusion and Final Thoughts

Featuring an interview with Dr Erika Hamilton, including the following topics: General overview of the mechanisms of action of endocrine-targeted therapies for breast cancer (0:00) Downregulation of estrogen receptor expression levels with endocrine therapy; therapeutic benefit of selective estrogen receptor degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) in ESR1 wild-type and ESR1-mutant breast cancer (5:11) Mechanisms of resistance to endocrine therapy (10:08) Efficacy and toxicities observed with SERDs and PROTACs for HR-positive breast cancer (15:26) Other applications for PROTACs (24:24) Emerging data from the Phase III evERA trial (27:38) Perspectives on clinical investigator and general medical oncologist practice pattern survey results (30:51) CME information and select publications

European Study of Prostate Cancer Screening — 23-Year Follow-upAssociation Between Baseline Diastolic Blood Pressure and the Efficacy of Intensive vs Standard Blood Pressure–Lowering TherapyFurther Reading* Effects of intensive blood-pressure control in type 2 diabetes mellitus* A Randomized Trial of Intensive versus Standard Blood-Pressure ControlSensible Medicine is 100% reader-supported. If you appreciate our work, consider becoming a free or paid subscriber. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

Dr. Aaron Zelikovich discusses a recent article on nipocalimab and its role in treating generalized myasthenia gravis.  Show citations:  Antozzi C, Vu T, Ramchandren S, et al. Safety and efficacy of nipocalimab in adults with generalised myasthenia gravis (Vivacity-MG3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2025;24(2):105-116. doi:10.1016/S1474-4422(24)00498-8

Show SummaryNatalie Elliott Handy, a caregiver for her husband and mother and co-host of the Confessions of a Reluctant Caregiver Podcast. During our conversation, we share the commitment that she and her sister have to highlighting and supporting military connected caregivers. Provide FeedbackAs a dedicated member of the audience, we would like to hear from you about the show. Please take a few minutes to share your thoughts about the show in this short feedback survey. By doing so, you will be entered to receive a signed copy of one of our host's three books on military and veteran mental health. About Today's GuestNatalie is someone who genuinely loves people. She has a natural passion for meeting new faces, staying closely connected with family, friends, and colleagues, and, most of all, helping others. Anyone who knows her will readily say, “Natalie doesn't know a stranger.” It's simply who she has always been.Raised in her family's hardware store, Natalie learned early how to engage customers — and how to count change — by talking to everyone who walked through the door. At church, she was the first to volunteer to sing, recite Bible verses in “big church,” and attend every youth activity, especially lock-ins. In school, her teachers often placed her in the front row to help minimize “distractions,” because she was, without a doubt, a social butterfly.Those gifts — her ability to connect, her quick wit, and her desire to support others — naturally led her into leadership roles throughout her career in the mental health field. She married young at 21 and, many years later, again at 39. She often describes her first marriage as a light-hearted “practice run” with someone kind, but not Jason, the partner she shares her life with today.From the outside, Natalie's life looked picture-perfect: a fulfilling job, a loving husband, a close-knit support system, and of course, her beloved dogs. But behind the scenes, she was burning the candle at both ends — working 12-hour days, six days a week, answering every request with, “No problem. Happy to help.”Everything shifted when Jason was diagnosed with cancer in March 2022. In the midst of that crisis, Natalie confronted the truth that she couldn't keep living at that pace. During those darkest moments, she reconnected with her faith and, through that, rediscovered her true self. She learned to acknowledge her imperfections and, more importantly, to love herself fully — flaws and all.Today, Natalie has reordered her life with clear priorities: God, herself, Jason, family and friends, and then work. She says “no” far more often, seeks silver linings in difficult moments, and is grateful for the journey that led her to live God's plan instead of her own. She embraces the mantra of being “perfectly imperfect.”Her mission is simple: to share stories and experiences that inspire, uplift, and — whenever possible — spark a little laughter. She strives to encourage others to be true to themselves while supporting the people they love. And along the way, she fully intends to keep making new friends.Links Mentioned During the EpisodeConfessions of a Reluctant Caregiver Website2024 Heroes Caring for Heroes series2023 Heroes Caring for Heroes seriesPsychArmor Resource of the WeekThis week's PsychArmor Resource of the Week is the PsychArmor course course Understanding the VA for Caregivers. This course helps caregivers navigate and better utilize the services of the VA – the largest integrated healthcare system in the country. The content for this course was developed collaboratively with a working group of various VA Departments. You can find the resource here:  https://learn.psycharmor.org/courses/understanding-the-va-for-caregivers-2 Episode Partner: Are you an organization that engages with or supports the military affiliated community? Would you like to partner with an engaged and dynamic audience of like-minded professionals? Reach out to Inquire about Partnership Opportunities Contact Us and Join Us on Social Media Email PsychArmorPsychArmor on XPsychArmor on FacebookPsychArmor on YouTubePsychArmor on LinkedInPsychArmor on InstagramTheme MusicOur theme music Don't Kill the Messenger was written and performed by Navy Veteran Jerry Maniscalco, in cooperation with Operation Encore, a non profit committed to supporting singer/songwriter and musicians across the military and Veteran communities.Producer and Host Duane France is a retired Army Noncommissioned Officer, combat veteran, and clinical mental health counselor for service members, veterans, and their families.  You can find more about the work that he is doing at www.veteranmentalhealth.com  

In this episode, Psychedelic Medicine Podcast host, Dr. Lynn Marie Morski, provides the latest updates from the field of psychedelic medicine. Dr. Morski discusses the breakthrough therapy designation which a number of psychedelic compounds have received in the past few years, the most recent of which is BPL-003, a nasal spray formulation of 5-MeO-DMT. One of the exciting aspects of this new compound, Dr. Morski notes, is that it is shorter-acting than most serotonergic psychedelics—a feature which may make treatment with this substance less expensive and more accessible.  Another exciting development is the COMPASS Pathways phase 3 trial of COMP360 psilocybin. Dr. Morski shares that the company believes they are nine to twelve months ahead of schedule, which means that if all goes well, this psilocybin compound could be approved for treatment resistant depression as early as sometime in 2027. She also discusses why the US FDA said they rejected MDMA for PTSD and what this governing body would like to see from subsequent research before reconsidering this decision. In closing, Dr. Morski shares excitement about the development of novel psychoplastogens—the non-hallucinogenic psychedelics—which may help bring many of the same healing benefits to populations currently unable to be served by the existing compounds under investigation.   In this episode, you'll hear: Which psychedelics currently have breakthrough therapy designation and for which indications Details of recent ketamine research for inpatient depression care and why these results are not as negative as they may seem The current horizons of psychedelic research and what indications may soon be explored Sources of hope in the current state of psychedelic research and the legal landscape   Quotes: "[BPL-003] showed rapid and durable antidepressant outcomes after a single dose. … here we have something that is under an hour [of psychedelic experience] for treatment resistant depression." [7:43] "Keeping patients blinded to whether or not they got the placebo or MDMA is a big focus that [the FDA] wanted to emphasize for these future phase 3 trials." [19:07] "I know we had a big setback last year. I think a lot of us thought by this time we'd be a year into MDMA being approved and we're not. However, there are so many things on the horizon that are worth being excited about." [23:48]   Links: Psychedelic Medicine Podcast on Instagram Psychedelic Medicine Podcast on YouTube Jelovac A, McCaffrey C, Terao M, et al. "Serial Ketamine Infusions as Adjunctive Therapy to Inpatient Care for Depression: The KARMA-Dep 2 Randomized Clinical Trial" JAMA Psychiatry, 2025. Beckley Psytech Limited Phase 2 Trial: BPL-003 Efficacy and Safety in Treatment Resistant Depression COMPASS Pathways Phase 3 Trial: Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD Food and Drug Administration (FDA) Complete Response Letter (CRL) to Lykos Therapeutics, declining to approve MDMA-assisted therapy for Posttraumatic Stress Disorder Psychedelic Alpha Psychedelic Drug Development Bullseye Chart Psychedelic Medicine Association Porangui

Struggle with your head held high!Text me at 972-426-2640 so we can stay connected!Support me on Patreon!Twitter:  @elliottspeaksInstagram: @elliottspeaks Text me at 972-426-2640 so we can stay connected!Support me on Patreon!Twitter: @elliottspeaksInstagram: @elliottspeaks